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Abstract: The steroid 5α-reductase type II enzyme catalyzes the conversion of testosterone 
(T) to dihydrotestosterone (DHT), and its deficiency leads to undervirilization in 46,XY 
individuals, due to an impairment of this conversion in genital tissues. Molecular analysis 
in the steroid 5α-reductase type II gene (SRD5A2) was performed in two 46,XY female 
siblings.  SRD5A2 gene sequencing revealed that the patients were homozygous for 
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p.Gln126Arg missense mutation, which results from the CGA > CAA nucleotide 
substitution. The molecular result confirmed clinical diagnosis of 46,XY disorder of sex 
development (DSD) for the older sister and directed the investigation to other family 
members. Studies on SRD5A2 protein structure showed severe changes at NADPH binding 
region indicating that structural modeling analysis can be useful to evaluate the deleterious 
role of a mutation as causing 5α-reductase type II enzyme deficiency. 
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1. Introduction 
The conversion of testosterone (T) in 5α-dihydrotestosterone (DHT) mediated by 5α-reductase type 
II enzyme is an essential process for the normal sexual differentiation of male external genitalia during 
fetal life [1].  
The decrease in the DHT synthesis due to mutations in the 5-reductase type II gene (SRD5A2) 
results in a disorder of sex development (DSD) in individuals with 46,XY karyotype [2–4]. DHT is the 
most potent androgen responsible for virilization of the external genitalia in embryonic life as well as 
for prostate differentiation and virilization at puberty. At birth, 46,XY affected individuals may exhibit 
genital ambiguity or female genitalia but, generally, normal internal reproductive structures [5–8]. In 
some cases, affected individuals are reared as females that will present spontaneous virilization at 
puberty [9]. 
The SRD5A2 gene is located at 2p23 and comprises five exons separated by four introns occupying 
approximately 60 kb of genomic DNA. The coding sequence is translated into a polypeptide of 254 
amino acids. The protein presents a testosterone binding domain and also a NADPH cofactor-binding 
domain in the N-terminal region. Mutations that affect the testosterone binding region are located in 
either exon 1 or 5, while mutations affecting the NADPH binding are more numerous and generally 
map within exon 3 and 4 [10,11]. 
In the present study, we have identified the p.Gln126Arg homozygous mutation in exon 2 of 
SRD5A2 gene in two 46,XY affected siblings raised as females. The SRD5A2 molecular diagnosis was 
important in this family to ensure an early identification of the enzymatic deficiency in a younger sib 
and to offer further appropriate medical and psychological support. 
2. Results and Discussion 
After studying and analyzing the SRD5A2 gene in case 1, the clinical suspicion of 5α-reductase type 
II deficiency was confirmed. The patient was informed about her diagnosis and about the possibility of 
gender reassignment. She was asked to bring her 10-year-old sister, who had not been diagnosed yet, 
to be evaluated.  
All five SRD5A2 exons were amplified by PCR for both patients. The molecular analysis revealed 
that both sisters were homozygous for p.Gln126Arg missense mutation. The mutation resulted from 
the CAA > CGA nucleotide substitution in the exon 2 (Figure 1). It is considered to completely 
inactivate the enzyme causing a drastic decrease in its half-life when transfected into mammalian cells Int. J. Mol. Sci. 2011, 12  
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in vitro [10,12]. This mutation had been previously described in Brazilian, Portuguese, French, Spanish, 
German, Belgium and North American patients and, in all cases, it was associated to severe phenotype of 
SRD5A2 deficiency [1,8–10,13–18]. Hackel et al. [8] described the compound heterozygosity for this 
mutation in four Brazilians patients. 
Figure 1. Electropherogram of part of exon 2: (A) Homozygous CAA > CGA nucleotide 
change in codon 126 identified in patient 1; (B) Normal CAA sequence in a control 
individual; (C) Multiple amino acid alignments with: human SRD5A2, human SRD5A1 
isoenzyme and enzymes of vertebrate animals’ orthologs. The glutamine residue (Q126)  
is shaded. The UniProt accession numbers for 5α-reductase protein sequences are:   
Homo sapiens (SRD5A2: P31213 and SRD5A1: P18405), Macaca fascicularis (SRD5A2: 
Q28892 and SRD5A1: Q28891), Sus scrofa (SRD5A2: O18765), Mus musculus (SRD5A2: 
Q99N99 and SRD5A1: Q68FF9), Rattus norvegicus (SRD5A2: P31214 and SRD5A1: 
P24008),  Bos taurus (SRD5A1: A5PJS2), Danio rerio (SRD5A1: A5PMI4), Oryzias 
latipes (SRD5A1: A5HL61), Xenopus tropicalis (SRD5A1: Q6DF23). 
 
 
 Int. J. Mol. Sci. 2011, 12  
 
9474
Figure 1(C) shows that Q126 residue is conserved in humans for both SRD5A1 and SRD5A2 
isoforms and also for proteins of several vertebrate animal orthologs. Therefore it is located in a very 
conserved region of the protein suggesting that this residue is very important for enzymatic structure 
and activity. 
The biological importance of p.Gln126Arg change upon the structure of the enzyme was investigated 
by modeling the mutant enzyme and comparing it to its native form. Because the crystallographic 
structure of SRD5A2 is not resolved yet we used Blast algorithm to search for a similar structure to be 
used in modeling analysis [19]. Around 30% similarity is usually required between sequences to obtain 
a reliable structural model [20], therefore the human liver 5β-reductase (AKR1D1) (PDB ID: 3G1R- 
chain A) that presented a similarity of 28.9% was chosen, since there was no other crystalographically 
resolved protein with higher similarity. The AKR1D1 is a human steroid 5β-reductase and belongs to 
the aldo/keto reductase family [21]. It is involved in the bile acid biosynthesis and also participates in 
the initial step of steroid hormone metabolism. In humans, steroid 5α-reductases (SRD5A1, SRD5A2) 
and steroid 5β-reductase (AKR1D1) act to yield the corresponding 5α- or 5β-dihydrosteroids, 
respectively [1,22]. The modeled structure indicated that p.Gln126Arg is located within an internal 
region of the protein near the NADPH-binding region (Figure 2(A)). The NADPH-binding domain in 
SRD5A2 comprises residues R145, R171, P181, G183, N193, G196 and R246 [10]. Observing the 
structural model, those amino acids are organized as a pocket to receive NADPH (Figure 2(A)). 
Different interactions were shown for either Q126 native residue or R126 mutant residues when 
comparing internal contacts (Figures 2(B–E)). Hydrogen bond interactions with Q182 (main chain–
side chain) and with both I131 and L130 (main chain–main chain) were maintained in both native and 
mutant proteins, whereas the aromatic interaction with Y132 was abolished and two different 
interactions with N122 (one hydrophobic and other hydrogen bond main chain–side chain) were 
established in the mutant. In addition, the R126 mutant residue demonstrated three different internal 
interactions: an aromatic stacking with Y129 and two hydrophobic interactions with A134 and C133. 
Either native or mutant 126 residue in SRD5A2 protein are linked through a hydrogen bond to Q182 
residue which is located within the NADPH-binding site region. However, the new hydrogen bond 
interaction between A134 and R126 mutant residue might affect the structure of NADPH-binding 
domain by disrupting the native interaction between A134 and Q182 residues (Figures 2(F,G)) and 
creating novel hydrophobic interaction between Q182 and I180 residues (Figures 2(H,I)). 
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Figure 2. (A) Modeled structure for the wild-type human 5α-reductase type II enzyme: 
Q126 native residue is denoted in red, and NADPH-binding site residues are illustrated in 
green; (B) Part of the modeled SRD5A2 structure showing internal contacts for Q126 
native residue; (C) Graphical representation for internal contacts of Q126 residue; (D) Part 
of the modeled SRD5A2 structure showing internal contacts for R126 mutant residue;   
(E) Graphical representation for internal contacts of R126 residue: interactions with 
different residues (A134, C133) are created, one interaction is suppressed (Y132) and two 
different interactions are established with N122 residue; (F) Graphical representation for 
internal contacts for A134 residue in the native protein: interactions with G184, Q182 and 
P106 are observed; (G) Graphical representation of internal contacts for A134 residue   
in the mutant protein: the novel interaction with R126 is observed; (H) Graphical 
representation of internal contacts for Q182 residue in the native protein; (I) Graphical 
representation of internal contacts for Q182 residue in the mutant protein: A134 interaction 
is abolished and a new contact with I180 is observed. Colored lines represent different types 
of interactions: black = main chain–main chain hydrogen bond; blue = side chain–main chain 
hydrogen bond; red = side chain–side chain hydrogen bond; gray = aromatic stacking; 
green = hydrophobic interaction. 
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Figure 2. Cont. 
Those results indicate that p.Gln126Arg mutation probably modify or abolish 5α-reductase type II 
enzyme activity by preventing NADPH binding.  
3. Experimental Section  
3.1. Patients 
A 17-year-old patient (case 1), reared as a girl, was referred to us to investigate virilization by the 
time of puberty. She was born at term after an uneventful pregnancy and normal delivery. She was the 
first child of consanguineous parents (first cousins); there were 3 paternal and 2 maternal half sibs,  
2 sisters and a brother. According to the patient, an ultrasound of her 10-year-old sister (case 2) revealed 
absence of uterus, therefore she was also suspected to have sex ambiguity (Figure 3). 
Figure 3. Family pedigree. 
 
On physical examination, her weight was 55 kg and height 175 cm. She exhibited an 8-cm phallus 
with chordee; a single perineal opening; no vaginal introitus; labioscrotal folds were fused, pigmented 
and enrugated; and 10 cm
3 testis were both palpable—the right was in the inguinal region and the left 
in the labioscrotal fold. Additionally, she had a male distribution of pubic hair, facial hair was absent 
and there was no breast development. She demonstrated a male gender behavior and considered herself 
as homosexual. 
The patient karyotype was 46,XY. Upon pelvic ultrasound, uterus was absent and prostate was also 
not detected. Hormonal evaluation showed elevated FSH (16 IU/L; normal male range (NR) 1.5–12.4), 
slightly elevated LH (8.7 IU/L; NR 1.7–8.6) and normal total testosterone (13.6 ng/mL; NR 8.8–27.0), 
and free testosterone (5 pg/mL; NR 2.8–8.1) levels, with low dihydrotestosterone level (0.3 ng/mL; Int. J. Mol. Sci. 2011, 12  
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NR 0.5–2.9), and high testosterone/dihydrotestosterone ratio (45.3; NR < 10). After 15 months of 
follow-up with psychological support, the patient requested sex reassignment to male. 
The patient’s sister (case 2) was 11 years old when first examined by us. On physical examination, 
her weight was 32.3 kg and height 143.6 cm. She exhibited a 2.5-cm phallus with chordee, a single 
perineal opening and no vaginal introitus. Labioscrotal folds were not enrugated or pigmented, and her 
gonads were not palpable; there were no signs of pubertal development. Her karyotype was 46,XY, 
and hormonal evaluation revealed prepubertal levels of FSH, LH and testosterone.  
When she was 12.5 years old, her phallus measured 4 cm and pubic hair was on Tanner stage 2. A 
few months later, hormonal evaluation revealed pubertal levels of FSH (7.75 IU/L), LH (5.3 IU/L), 
and total (9.6 ng/mL) and free testosterone (5.85 pg/mL), low dihydrotestosterone level (0.2 ng/mL), 
and high testosterone/dihydrotestosterone ratio (48.0). The gonads were not seen upon pelvic 
ultrasound. When she was last seen by us, at 13.5 years, her phallus measured 5 cm and pubic hair was 
on Tanner stage 3. 
As soon as the diagnosis of 5-alpha-reductase type 2 deficiency was confirmed, a careful approach 
was conducted to explain her condition, which was favored by her knowledge about what was going 
on with her older sister. Since then, she has been followed by a specialized psychologist who has 
evaluated her periodically for her understanding and adapting to male gender. At the beginning, she 
revealed interest in situations which are socially viewed as male activities, such as playing soccer with 
boys and watching action movies, and using clothes which were not typically female, although, at first, 
she did not see herself as a male. At the present, she exhibits overtly male behavior.  
3.2. Methods  
Genomic DNA was obtained from peripheral blood by proteinase K/phenol extraction method. SRD5A2 
gene molecular analysis was performed by PCR amplification of the five exons (Table 1). PCR products 
were directly sequenced using Big Dye
® Terminator Cycle Sequencing Kit V3.1 Ready Reaction   
(ABI PRISM/PE Biosystems). Sequences were obtained in an ABI 3700 Sequencer (ABI PRISM/PE 
Biosystems) and were compared to the SRD5A2  normal sequence (ENSEMBL—ENSG00000049319) 
using Chromas (reduced version-free software) and CLC Sequence Viewer v.6.0 (free software).  
Table 1. Primers used for PCR and sequencing of the SRD5A2 gene. 
Exon  Forward Primer  Reverse Primer 
Ta* 
(°C) 
Fragment size 
(pb) 
1  GCAGCGGCCCACCGGCGAGGAACA TGGACGCCGGGAGCAGGGCAGT 66  369 
2  CAGTGAATCCTAACCTTTCCTCCC TTGTTAGCTGGGAAGTAGGTGGAG  59.5  243 
3  AAGCACCACAATCTGGACACAT CTCCAGGGAAGAGTGAGAGTCTG 59.5  203 
4  CAATGATTGACCTTCCGATTCTTC GTTTGGAGAAGAAGAAAGCTACGT 63  238 
5  TCAGCCACTGCTCCATTATATTTA TTGACAGTTTTCATCCAGCATTGTG 59.5  171 
* Ta = annealing temperatures used in PCRs. 
Theoretical structure of human 5α-reductase type II has been modeled using human liver 5β- reductase 
(AKR1D1) (PDB ID: 3G1R- chain A) as template. The models have been created and validated by default 
settings and parameters of the SWISS MODEL web-served program. The modeled protein structure was 
produced and analyzed by the web-based program BlueStarSTING [23]. Int. J. Mol. Sci. 2011, 12  
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4. Conclusions 
The present molecular investigation collaborated in guiding the diagnosis of deficiency in   
5α-reductase type II in a family. The molecular analysis provided additional support for the psychosocial 
male orientation for both female affected siblings that, in the case of the older sister, had been defined 
even before the diagnosis. Therefore, the identification SRD5A2 gene mutations contributed in 
confirming the diagnosis and provided an early diagnosis of a non-symptomatic affected member in the 
family. Additionally, the structural analysis of the mutated protein demonstrated to be a useful and 
inexpensive tool to evaluate the deleterious role of a mutation as a cause of the deficiency of   
5α-reductase type II enzyme.  
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